CD30


Also found in: Wikipedia.

CD30

a type I transmembrane protein present on activated T and B cells that may play a role in cell activation and/or differentiation; expressed in Hodgkin disease, some T-cell lymphomas, and anaplastic large cell lymphomas.
References in periodicals archive ?
Kiniksa is evaluating the progression of KPL-045, a monoclonal antibody inhibitor of the CD30 ligand co-stimulatory molecule, based on preclinical data from the program in the context of the company's portfolio.
Adcetris is an antibody-drug conjugate directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas.
LyP is part of a spectrum of CD30 (Ki-1)-positive cutaneous lymphoproliferative diseases (CD30+ LPDs), including lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline CD30+ lesions.5 The pathophysiology of CD30+ LPDs, including LyP, is largely unknown.6 CD30 signaling is known to have an effect on the growth and survival of lymphoid cells, and one hypothesis is that genetic instability and accumulated genetic defects may have a role in the development of LyP and the progression to associated neoplasms.7
PC-ALCL is a CD30+ lymphoproliferative disorder of the skin consisting of cells with an anaplastic, pleomorphic, or immunoblastic cytomorphology with > 75% of the tumor cells expressing CD30 (Ki1) antigen.
Eventually the patient underwent left pneumonectomy with final histology including immunohistochemistry demonstrating anaplastic large cell lymphoma positive for CD30, Ki-67, CD45, and ALK-1 (Figure 4).
Since October 2016, pretransplant determination of the immune activation marker soluble CD30 (sCD30) in ELISA has also become an important component of pretransplant risk estimation in measure 1 of the Heidelberg Algorithm because pretransplant activation of the immune system, as measured by high sCD30 levels, was in two recent studies of 80 presensitized high-risk patients from Heidelberg and 385 presensitized patients from 13 transplant centers (corresponding to a series of some 1000 patients) found to be a substantial risk factor for graft loss in the presence of DSA (see below) [3, 7].
CD30 is a member of the tumor necrosis factor/nerve growth factor receptor superfamily [8], which is preferentially expressed by human T cell clones producing T helper (Th) type 2 cytokines, and can be released in a soluble form (sCD30) by activated cells [8, 9].
It has been listed as a primary, cutaneous, CD30 (+) lymphoproliferative disorder in the current World Health Organization (WHO) and European Organization for Research and Treatment of Cancer (EORTC) classification [1].
Immunohistochemical analysis demonstrated strong CD30, CD43, and MUM1 expression, while EMA was weakly positive (Figure 5).